Cargando…
Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714719/ https://www.ncbi.nlm.nih.gov/pubmed/34662892 http://dx.doi.org/10.1182/bloodadvances.2021005966 |
_version_ | 1784623960838635520 |
---|---|
author | Carney, Brian J. Wang, Tzu-Fei Ren, Siyang George, Gemlyn Al Homssi, Amer Gaddh, Manila Connolly, Gregory C. Shah, Vinay I. Bogue, Thomas Bartosic, Abigail Neuberg, Donna Baumann Kreuziger, Lisa Zwicker, Jeffrey I. |
author_facet | Carney, Brian J. Wang, Tzu-Fei Ren, Siyang George, Gemlyn Al Homssi, Amer Gaddh, Manila Connolly, Gregory C. Shah, Vinay I. Bogue, Thomas Bartosic, Abigail Neuberg, Donna Baumann Kreuziger, Lisa Zwicker, Jeffrey I. |
author_sort | Carney, Brian J. |
collection | PubMed |
description | Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a prospective, multicenter, observational study. Patients with active malignancy, acute VTE, and concurrent thrombocytopenia (platelet count <100 000/µL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a competing risk. Primary outcomes were centrally adjudicated and comparisons made according to initial treatment with full-dose or modified-dose anticoagulation. A total of 121 patients were enrolled at 6 hospitals. Seventy-five patients were initially treated with full-dose anticoagulation (62%) and 33 (27%) with modified-dose anticoagulation; 13 (11%) patients received no anticoagulation. Most patients who received modified-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis (28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% confidence interval [CI], 4.9-20.8) and 6.6% (95% CI, 2.4-15.7) in those who received modified-dose anticoagulation (Fine-Gray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60 days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11) and 0% in patients who received modified-dose anticoagulation. In conclusion, modified-dose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia. |
format | Online Article Text |
id | pubmed-8714719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-87147192021-12-29 Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study Carney, Brian J. Wang, Tzu-Fei Ren, Siyang George, Gemlyn Al Homssi, Amer Gaddh, Manila Connolly, Gregory C. Shah, Vinay I. Bogue, Thomas Bartosic, Abigail Neuberg, Donna Baumann Kreuziger, Lisa Zwicker, Jeffrey I. Blood Adv Thrombosis and Hemostasis Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. To assess the incidence of hemorrhage or thrombosis according to anticoagulation strategy, we performed a prospective, multicenter, observational study. Patients with active malignancy, acute VTE, and concurrent thrombocytopenia (platelet count <100 000/µL) were enrolled. The cumulative incidences of hemorrhage or recurrent VTE were determined considering death as a competing risk. Primary outcomes were centrally adjudicated and comparisons made according to initial treatment with full-dose or modified-dose anticoagulation. A total of 121 patients were enrolled at 6 hospitals. Seventy-five patients were initially treated with full-dose anticoagulation (62%) and 33 (27%) with modified-dose anticoagulation; 13 (11%) patients received no anticoagulation. Most patients who received modified-dose anticoagulation had a hematologic malignancy (31 of 33 [94%]) and an acute deep vein thrombosis (28 of 33 [85%]). In patients who initially received full-dose anticoagulation, the cumulative incidence of major hemorrhage at 60 days was 12.8% (95% confidence interval [CI], 4.9-20.8) and 6.6% (95% CI, 2.4-15.7) in those who received modified-dose anticoagulation (Fine-Gray hazard ratio, 2.18; 95% CI, 1.21-3.93). The cumulative incidence of recurrent VTE at 60 days in patients who initially received full-dose anticoagulation was 5.6% (95% CI, 0.2-11) and 0% in patients who received modified-dose anticoagulation. In conclusion, modified-dose anticoagulation appears to be a safe alternative to therapeutic anticoagulation in patients with cancer who develop deep vein thrombosis in the setting of thrombocytopenia. American Society of Hematology 2021-12-20 /pmc/articles/PMC8714719/ /pubmed/34662892 http://dx.doi.org/10.1182/bloodadvances.2021005966 Text en © 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
spellingShingle | Thrombosis and Hemostasis Carney, Brian J. Wang, Tzu-Fei Ren, Siyang George, Gemlyn Al Homssi, Amer Gaddh, Manila Connolly, Gregory C. Shah, Vinay I. Bogue, Thomas Bartosic, Abigail Neuberg, Donna Baumann Kreuziger, Lisa Zwicker, Jeffrey I. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title | Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title_full | Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title_fullStr | Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title_full_unstemmed | Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title_short | Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
title_sort | anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study |
topic | Thrombosis and Hemostasis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714719/ https://www.ncbi.nlm.nih.gov/pubmed/34662892 http://dx.doi.org/10.1182/bloodadvances.2021005966 |
work_keys_str_mv | AT carneybrianj anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT wangtzufei anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT rensiyang anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT georgegemlyn anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT alhomssiamer anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT gaddhmanila anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT connollygregoryc anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT shahvinayi anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT boguethomas anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT bartosicabigail anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT neubergdonna anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT baumannkreuzigerlisa anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT zwickerjeffreyi anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy AT anticoagulationincancerassociatedthromboembolismwiththrombocytopeniaaprospectivemulticentercohortstudy |